title: Lipoprotein lipase activator NO-1886 improves fatty liver caused by high-fat feeding in streptozotocin-induced diabetic rats.
abstract: NO-1886 is a lipoprotein lipase (LPL) activator. Administration of NO-1886 results in an increase in plasma high-density lipoprotein cholesterol (HDL-C) and a decrease in plasma triglyceride (TG) levels. The aim of this study was to ascertain whether NO-1886 improves fatty liver caused by high-fat feeding in streptozotocin (STZ)-induced diabetic rats. Administration of NO-1886 resulted in increased plasma HDL-C levels and decreased TG levels without affecting total cholesterol and glucose levels in the diabetic rats. NO-1886 dose-dependently decreased liver TG contents and cholesterol contents, resulting in improvement of fatty liver. NO-1886 also reduced plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) that accompany fatty liver. The liver cholesterol contents were inversely correlated with plasma HDL-C levels (r = -0.5862, P <.001) and were positively correlated with plasma TG levels (r = 0.4083, P <.003). The liver TG contents were inversely correlated with plasma HDL-C levels (r = -0.6195, P <.001) and were positively correlated with plasma TG levels (r = 0.5837, P <.001). There was no correlation between plasma cholesterol levels, and cholesterol and TG contents in liver. These results indicate that reducing plasma TG levels and elevating in HDL-C levels may result in improving fatty liver.
authors.affiliation: Faculty of Medicine, Aichi Medical University, Aichi, Japan.
authors.forename: Masataka
authors.initials: M
authors.lastname: Kusunoki
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Tsutsumi
authors.forename: Yasuhide
authors.initials: Y
authors.lastname: Inoue
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Hara
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Miyata
authors.forename: Takao
authors.initials: T
authors.lastname: Nakamura
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Ogawa
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Sakakibara
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Fukuzawa
authors.forename: Naomi
authors.initials: N
authors.lastname: Okabayashi
authors.forename: Koich
authors.initials: K
authors.lastname: Kato
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ikeda
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Kurokawa
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Kazuo
authors.initials: K
authors.lastname: Otake
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Nakaya
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001549:Benzamides / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D004032:Diet; D004041:Dietary Fats / Q000494:pharmacology*; D020536:Enzyme Activators / Q000494:pharmacology*; D005234:Fatty Liver / Q000139:chemically induced / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008071:Lipoprotein Lipase / Q000378:metabolism*; D008297:Male; D009929:Organ Size / Q000187:drug effects; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D001549:Benzamides; D001786:Blood Glucose; D004041:Dietary Fats; D020536:Enzyme Activators; D008055:Lipids; D009943:Organophosphorus Compounds; C082137:4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D008071:Lipoprotein Lipase